Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GLyPharma
Montreal, Quebec, Canada
- Ownership
- Private
- Development stage
- Other
01
Overview
GLyPharma developed the GLP-2 analog apraglutide, initially targeting short bowel syndrome (SBS) and rare GI diseases. The program was acquired pre-commercialization and after Phase 1 studies in healthy volunteers. Its compound was later successfully advanced in SBS, earning orphan drug designation.
- Therapeutic areas
- OncologyGastroenterology
- Modalities
- PeptidesSmall molecule
- Industry
- Biotech
02
Partnerships
Ferring PharmaceuticalsFonds de solidarité FTQCTI Life Sciences Fund
Beyond the preview
Go deeper on GLyPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLyPharma.